Two biotech companies, Clontech Laboratories, Inc. (Mountain View, CA, USA) and Tet Systems (Heidelberg, Germany) have amended their existing license agreement. The new arrangement will grant Clontech rights to develop, manufacture, and commercialize novel Tet Systems products such as the Tet-On 3G Inducible Expression System.
The Tet-System currently marketed by Clontech has already become a highly regarded method for regulated gene expression, as attested by more than 7,000 peer-reviewed scientific publications. The new Tet-On 3G Inducible Expression System offers researchers even greater control of gene regulation through lower expression in the noninduced state, even in transient transfection settings. These benefits were obtained by incorporating an improved transcriptional activator and a novel minimal Tet promoter.
The system's ten-fold increased sensitivity for the inducing agent (doxycycline) will also expand the long-established benefits of dynamic transactivation, particularly for in vivo models.
Clontech is launching a broad suite of Tet-On 3G Inducible Expression Systems, including different promoters and fluorescent markers. Carol Lou, general manager of Clontech Laboratories, Inc., said, "Clontech has a long history of leadership in developing technologies for gene delivery and expression, and a long-standing partnership with TET Systems. We are pleased to continue and extend this history by adding the Tet-On 3G Inducible Expression System to our portfolio of Tet System products.”
Related Links:
Clontech Laboratories, Inc.
Tet Systems
